title: [Preparation and evaluation of RGD and TAT co-modified paclitaxel loaded liposome].
abstract: OBJECTIVE
  To prepare Arg-Gly-Asp (RGD) and cell penetrating peptide TAT co-modified paclitaxel loaded liposome (RGD/TAT-LP-PTX) for MCF-7 cell inhibition.
  
  
  METHODS
  The co-modified liposome was prepared by film-ultrasonic method. The appearance, particle size and zeta potential were evaluated. The cellular uptake by MCF-7 cells in vitro was used to evaluate the targeting efficiency. The anti-proliferation efficiency of RGD/TAT-LP-PTX was evaluated by MTT assay. Tumor spheroids were used to evaluate anti-tumor ability of RGD/TAT-LP-PTX in vitro.
  
  
  RESULTS
  The particle diameter of the co-modified liposome was (138.8 ± 12.4) nm with the Zeta potential of (25.85 ± 2.75) mV. The entrapment efficiency of PTX was 88.3%. The RGD/TAT-LP uptaken by MCF-7 cells at 4 h was 1.79 times higher than that at 2 h. The co-modified liposome uptaken by MCF-7 cells was 2.25 and 2.72 times higher than that of TAT-LP and RGD-LP, respectively. The anti-proliferation rate of RGD/TAT-LP-PTX increased with time. The inhibition rate of RGD/TAT-LP-PTX for MCF-7 cells at 48 h was 1.78 times higher than that at 24 h. The MTT assay demonstrated the cell viability of RGD/TAT-LP-PTX was 1.65, 1.82 and 2.55 times higher than that of TAT-LP-PTX, RGD-LP-PTX and LP-PTX, respectively.
  
  
  CONCLUSIONS
  Co-modified liposome may serve as a promising breast cancer delivery system for antitumor drugs.
authors.affiliation: Emergency Department, Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China gaobohbykd@163.com.
authors.forename: Bo
authors.initials: B
authors.lastname: Gao
authors.forename: Weixin
authors.initials: W
authors.lastname: Mu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms; D002470:Cell Survival; D006801:Humans; D008081:Liposomes; D061986:MCF-7 Cells / Q000187:drug effects; D009842:Oligopeptides / Q000737:chemistry*; D017239:Paclitaxel / Q000494:pharmacology*; D010316:Particle Size; D010446:Peptide Fragments / Q000737:chemistry*; D018874:Spheroids, Cellular / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; D009842:Oligopeptides; D010446:Peptide Fragments; C047981:arginyl-glycyl-aspartic acid; D017239:Paclitaxel